Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.59 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.59 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075257 | 0.90 | NPBWR1 (0.56) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL24075252 | 0.83 | KDM4E (0.69) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL24074355 | 0.82 | NPBWR1 (0.56) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL24075038 | 0.82 | RHEB (0.68) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL24075315 | 0.82 | NPBWR1 (0.68) | NPBWR1DGAT1KCNH2SOAT1 | |
| SCHEMBL15245140 | 0.81 | DGAT1 (0.67) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL900794 | 0.81 | NPBWR1 (0.74) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL10325105 | 0.81 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL14669363 | 0.80 | HPGD (0.47) | NPBWR1DGAT1KCNH2SOAT1TRPV1 | |
| SCHEMBL21086936 | 0.80 | NPBWR1 (0.61) | NPBWR1DGAT1KCNH2SOAT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021242790-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192626-A1 | NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | EPHX1, EPHX2, NCEH1 | NPBWR1 1635/4885DGAT1 563/4885KCNH2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.